Quantcast

FDA CONSUMER HEALTH INFORMATION – Concentration Lowered in Tamiflu Medication

July 13, 2011

SILVER SPRING, Md., July 13, 2011 /PRNewswire-USNewswire/ — When flu season arrives this fall, a liquid form of Tamiflu–the most widely used anti-viral flu medication–will be available in a new, lower concentration to reduce the possibility of medication errors.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The change applies to the oral suspension form of Tamiflu. Oral suspension is a powder form of the prescription medication that a pharmacist mixes with water to make a liquid treatment easier to take by children or adults who are unable to swallow a Tamiflu capsule.

The Tamiflu packaging of its oral suspension product says “new strength,” meaning that the concentration of medicine in the liquid has been changed from 12 mg/mL (milligrams per milliliter) to 6 mg/mL. Why was it changed? Because the higher concentration medication became frothy when mixed, making it difficult to measure the correct dose.

Learn more about this change in one form of this popular flu medication at

http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm262710.htm

Sign up for e-mail notices of new FDA Consumer Updates at

https://service.govdelivery.com/service/subscribe.html?code=USFDA_9

View the FDA Consumer Update RSS feed at http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/Consumers/rss.xml

FDA Consumer Updates may be posted and published elsewhere without permission. Please credit “FDA Consumer Health Information (www.fda.gov/consumer)” as the source. FDA values feedback on its consumer health information. Send questions, comments, or story ideas to: consumerinfo@fda.hhs.gov.

Media Contact: Jason Brodsky, 301-796-8234, Jason.Brodsky@fda.hhs.gov

SOURCE U.S. Food and Drug Administration


Source: newswire



comments powered by Disqus